RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hikma Pharmaceuticals Stock

Hikma Pharmaceuticals EBIT 2024

Hikma Pharmaceuticals EBIT

683.91 M USD

Ticker

HIK.L

ISIN

GB00B0LCW083

WKN

A0HG69

In 2024, Hikma Pharmaceuticals's EBIT was 683.91 M USD, a 9.95% increase from the 622 M USD EBIT recorded in the previous year.

The Hikma Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2029e-
2028e855.69
2027e815.25
2026e767.72
2025e725.7
2024e683.91
2023622
2022509
2021559
2020526
2019474
2018449
2017386
2016419
2015381
2014402
2013352
2012166.8
2011118.7
2010127.9
2009114.7
200894.3
200792.4
200674.3
200567.8
200461.2

Hikma Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hikma Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hikma Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hikma Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hikma Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hikma Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hikma Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hikma Pharmaceuticals’s growth potential.

Hikma Pharmaceuticals Revenue, EBIT and net profit per share

DateHikma Pharmaceuticals RevenueHikma Pharmaceuticals EBITHikma Pharmaceuticals Net Income
2029e3.74 B undefined0 undefined0 undefined
2028e3.62 B undefined855.69 M undefined629.29 M undefined
2027e3.48 B undefined815.25 M undefined610.14 M undefined
2026e3.39 B undefined767.72 M undefined568.22 M undefined
2025e3.24 B undefined725.7 M undefined522.59 M undefined
2024e3.13 B undefined683.91 M undefined493.24 M undefined
20232.88 B undefined622 M undefined190 M undefined
20222.52 B undefined509 M undefined188 M undefined
20212.55 B undefined559 M undefined421 M undefined
20202.34 B undefined526 M undefined431 M undefined
20192.2 B undefined474 M undefined486 M undefined
20182.08 B undefined449 M undefined282 M undefined
20171.94 B undefined386 M undefined-843 M undefined
20161.95 B undefined419 M undefined155 M undefined
20151.44 B undefined381 M undefined252 M undefined
20141.49 B undefined402 M undefined278 M undefined
20131.37 B undefined352 M undefined212 M undefined
20121.11 B undefined166.8 M undefined100.3 M undefined
2011918 M undefined118.7 M undefined80.1 M undefined
2010730.9 M undefined127.9 M undefined98.8 M undefined
2009636.9 M undefined114.7 M undefined77.7 M undefined
2008580.7 M undefined94.3 M undefined57.1 M undefined
2007448.8 M undefined92.4 M undefined62.6 M undefined
2006317 M undefined74.3 M undefined54.5 M undefined
2005262.2 M undefined67.8 M undefined43.9 M undefined
2004214.1 M undefined61.2 M undefined37.5 M undefined

Hikma Pharmaceuticals stock margins

The Hikma Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hikma Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hikma Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hikma Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Hikma Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hikma Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hikma Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hikma Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hikma Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hikma Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hikma Pharmaceuticals Margin History

Hikma Pharmaceuticals Gross marginHikma Pharmaceuticals Profit marginHikma Pharmaceuticals EBIT marginHikma Pharmaceuticals Profit margin
2029e48.94 %0 %0 %
2028e48.94 %23.61 %17.36 %
2027e48.94 %23.46 %17.56 %
2026e48.94 %22.67 %16.78 %
2025e48.94 %22.38 %16.12 %
2024e48.94 %21.84 %15.75 %
202348.94 %21.63 %6.61 %
202250.26 %20.22 %7.47 %
202150.96 %21.9 %16.49 %
202051.82 %22.47 %18.41 %
201949.7 %21.52 %22.06 %
201851.64 %21.63 %13.58 %
201750.26 %19.94 %-43.54 %
201652.21 %21.49 %7.95 %
201556.81 %26.46 %17.5 %
201457.15 %27 %18.67 %
201355.97 %25.79 %15.53 %
201245.2 %15.04 %9.05 %
201143.06 %12.93 %8.73 %
201048.88 %17.5 %13.52 %
200947.79 %18.01 %12.2 %
200844.17 %16.24 %9.83 %
200749.35 %20.59 %13.95 %
200650 %23.44 %17.19 %
200551.79 %25.86 %16.74 %
200451.47 %28.58 %17.52 %

Hikma Pharmaceuticals Aktienanalyse

What does Hikma Pharmaceuticals do?

Hikma Pharmaceuticals PLC is a global company that focuses on the manufacturing and distribution of high-quality generics and specialty medications. The company was founded in Jordan in 1978 and is headquartered in London, UK. Over the years, Hikma Pharmaceuticals PLC has consistently grown and is now one of the leading generic manufacturers worldwide. The company operates in three core business areas: generics, injectables, and branded pharmaceuticals. It specializes in producing medications for diseases such as HIV/AIDS, cancer, and cardiovascular diseases. It also manufactures generics for anesthesia and opioid painkillers. In addition, Hikma Pharmaceuticals PLC produces injectable medications, particularly sterile injectables, used in emergency medicine, intensive care, and oncology. The company also develops proprietary medications based on specific patient needs and has its own pipeline of branded pharmaceuticals. It distributes over 1,000 medications in more than 50 countries, with production facilities in several countries including Jordan, Saudi Arabia, Portugal, Italy, and the United States. Hikma Pharmaceuticals PLC has shown strong performance in recent years, reflected in positive financial results. It prioritizes efficient production, strict quality standards, and smart investments to strengthen its market presence and innovation capability. The company has built a reputation as a reliable partner for customers and investors. In summary, Hikma Pharmaceuticals PLC is a global company engaged in the production and distribution of generics, injectables, and proprietary medications. It is known for its high-quality and cost-effective generics, broad product range, and strong international network. The company has established itself as a trusted partner for customers and investors and will continue to play a significant role in the pharmaceutical industry. Hikma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Hikma Pharmaceuticals's EBIT

Hikma Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Hikma Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Hikma Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Hikma Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Hikma Pharmaceuticals stock

How much did Hikma Pharmaceuticals achieve in EBIT for the current year?

In the current year, Hikma Pharmaceuticals has achieved an EBIT of 683.91 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Hikma Pharmaceuticals.

How has the EBIT of Hikma Pharmaceuticals developed in recent years?

The EBIT of Hikma Pharmaceuticals has increased by 9.953% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Hikma Pharmaceuticals?

The EBIT of Hikma Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Hikma Pharmaceuticals pay?

Over the past 12 months, Hikma Pharmaceuticals paid a dividend of 0.49 USD . This corresponds to a dividend yield of about 1.98 %. For the coming 12 months, Hikma Pharmaceuticals is expected to pay a dividend of 0.52 USD.

What is the dividend yield of Hikma Pharmaceuticals?

The current dividend yield of Hikma Pharmaceuticals is 1.98 %.

When does Hikma Pharmaceuticals pay dividends?

Hikma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of September, April, September, September.

How secure is the dividend of Hikma Pharmaceuticals?

Hikma Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hikma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.52 USD are expected. This corresponds to a dividend yield of 2.08 %.

In which sector is Hikma Pharmaceuticals located?

Hikma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hikma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hikma Pharmaceuticals from 9/20/2024 amounting to 0.32 USD, you needed to have the stock in your portfolio before the ex-date on 8/16/2024.

When did Hikma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Hikma Pharmaceuticals in the year 2023?

In the year 2023, Hikma Pharmaceuticals distributed 0.442 USD as dividends.

In which currency does Hikma Pharmaceuticals pay out the dividend?

The dividends of Hikma Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Hikma Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Hikma Pharmaceuticals

Our stock analysis for Hikma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hikma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.